Contents:
Document Title
Management of Hypercalcaemia of Malignancy
Document Date
January 2023
Document Purpose and Intended Audience
To support specialist palliative care clinicians in hospices and hospital trusts to manage and treat hypercalcaemia related to malignancy.
Authors
Radka Klezlova, Consultant in Palliative Medicine, Walsall Healthcare NHS Trust Chantal Meystre, Consultant in Palliative Medicine, HEFT NHS Trust
References
Palliative Care Formulary 8th Edition 2022 Twycross, R. Symptom Management in Advanced Cancer British National Formulary 71st Edition 2016 NHS Scotland – Scottish Palliative Care Guidelines – accessed via
Consultation Process
Circulated to SPAGG group for comments and approval
Monitoring
This guideline will be audited by members of the group every 3 years.
Review Date
(must be within three years)
January 2026
Michelle Aslett Pharmacist, Marie Curie
Nik Sanyal Consultant in Palliative Medicine, Coventry and Warwickshire
Laura Dewhirst Palliative Care Registrar
Alice Gray Palliative Care Registrar
Approval Signatures:
SPAGG chair
Dr Jon Tomas
SPAGG secretary
Dr Emma Wooldridge
Date Approved by SPAGG: 10/7/2019
Date submitted to Area Prescribing Committee: N/A
Version History
Version 0.1
Date
Sept 2015
Summary of change/ process
Guidelines written by Dr Chantal Meystre and Dr Radka Klezlova amalgamated into SPAGG format. For circulation to SPAGG.
Version 0.2
Date
April 2016
Summary of change/ process
Guidelines reviewed by Michelle Aslett and Jo Bartlett and changes made based on comments from the group. For presentation at SPAGG on 20/4/16.
Version 0.3
Date
May 2019
Summary of change/ process
Guidelines were reviewed by Brenda Ward and Radka Klezlova. Paragraphs about aetiology of hypercalcaemia of malignancy and other treatment options - Calcitonin and Denosumab were added.
Version 0.4
Date
Jan 2023
Summary of change/ process
Guidelines reviewed by Laura Dewhirst and Alice Gray changes made based on comments from the group. Emphasis placed on reviewing the need for treating hypercalcaemia and flow chart updated
Disclaimer
These Guidelines are intended for use by healthcare professionals and the expectation is that they will use clinical judgement, medical, and nursing knowledge in applying the general principles and recommendations contained within. They are not meant to replace the many available texts on the subject of palliative care.
Some of the management strategies describe the use of drugs outside their licensed indications. They are, however, established and accepted good practice. Please refer to the current BNF for further guidance.
Whilst SPAGG takes every care to compile accurate information , we cannot guarantee its correctness and completeness, and it is subject to change. We do not accept responsibility for any loss, damage or expense resulting from the use of this information.